About: Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.32 (-0.23%)
RZLT NASDAQ Rezolute Inc
Rezolute Inc share price
RZLT price activity
Último preço
$ 4,320
Variação (24h)
-0,01 USD (-0,23%)
Volume
2.19M
Volume (média 4 sem.)
-
Abertura
$ 4,64
Variação do dia
$ 4,15 - $ 4,64
Fechamento anterior
$ 4,33
Último negócio
06 Oct, 8:00 pm GMT+0
Atrasado
06 Oct, 8:00 pm GMT+0
RZLT price performance
Atrasado
06 Oct, 8:00 pm GMT+0
quote.marketSignals